Non-target screening using chromatography coupled to high-resolution mass spectrometry is a powerful tool in environmental ...

Learn how physics and programming come together in this Python simulation of elastic collisions! In this tutorial, we explore the fundamental principles of momentum and energy conservation while ...

Just follow my lead!

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Novo Nordisk (CPSE:NOVO B) has filed legal action against ...

GLP-1 weight-loss drugs are now the focus of a heated legal battle, with a leading drugmaker warning that copycat versions pose a risk to patient safety. "When you go and try to source raw materials ...

Pharmaceutical giant Novo Nordisk announced Monday it is suing telemedicine platform Hims & Hers for allegedly “deceiving patients and putting their health at risk” by selling compounded versions of ...

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up for any (or all) of our 25+ Newsletters. Some states have laws and ethical rules regarding solicitation and ...

Share on Pinterest Hims & Hers has withdrawn its low cost compounded weight loss pill after pressure from top U.S. health officials and a major lawsuit. Image courtesy of Novo Nordisk Hims & Hers ...

Novo Nordisk is asking the court to permanently ban Hims from selling compounded versions of its drugs that infringe on the company's patents, and is seeking to recover damages. The move escalates the ...

A high-profile fight in the world of compounded drugs looks like it has been resolved, with telehealth firm Hims & Hers (HIMS) backing off a plan to offer a knockoff Wegovy pill for as little as $49 ...

Novo Nordisk has sued Hims for allegedly violating patents protecting semaglutide, seeking potentially “hundreds of millions” in damages, John Kuckelman, the pharma’s general counsel, said. The ...

THE WHAT? The US Food and Drug Administration plans to take enforcement action against companies marketing non-FDA-approved compounded GLP-1 drugs as alternatives to approved weight-loss and diabetes ...